Find your next paid study

~$150 – $4,500

Actual pay is set by the research site.

BayerNCT06764316

Obesity, MorbidMetabolic SyndromeNASH - Nonalcoholic Steatohepatitis

Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach

Variable outcomes after weight loss surgery are likely attributable to complex, poorly understood mechanisms. Due to the significant impact that morbid obesity…

University of Missouri-ColumbiaNCT04841057

Actual pay is set by the research site.

Phase 2

A Phase 2, Open-label, Fixed-dose Study to Assess the Efficacy of Sodium Phenylbutyrate (ACER-001) in Treating Pediatric and Adult Patients With Medium Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency Resulting From the Prevalent ACADM c.985 A>G (K304E) Mutation

This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency…

Medium-chain Acyl-CoA Dehydrogenase Deficiency

Jerry Vockley, MD, PhDNCT06773026

~$75 – $3,000

Actual pay is set by the research site.

Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors

Background: Researchers seek ways to study people s medical problems in order to teach and further general knowledge. The ability to assess and treat people w…

Wide Spectrum of DiseasesHematologic Diseases

National Heart, Lung, and Blood Institute (NHLBI)NCT04450927

~$10 – $675

Actual pay is set by the research site.

Phase 1

Therapeutic RSK1 Targeting in Myeloid Malignancies

This study hypothesizes that PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), is safe and well tolerated in participants with myelofibrosis…

Myeloid Malignancy

Washington University School of MedicineNCT07379125

~$150 – $3,000

Actual pay is set by the research site.

Tear Fluid Collection in Patients Before and After Corneal Incision or Trauma.

Tear fluid will be collected from patients diagnosed with ocular trauma at the University of Pittsburgh Medical Center to evaluate biomarkers.

Ocular Trauma

InnSight Technology, Inc.NCT07887425

~$10 – $1,050

Actual pay is set by the research site.

Phase 1

A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 adm…

LiposarcomaProstate CancerAdvanced Breast Cancer+2 more

~$150 – $4,500

Actual pay is set by the research site.

PfizerNCT04557449

HealthyAnkle Foot Orthosis (AFO)Peripheral Neuropathy

Reliability of Force Measurement Within the Carbon Fiber Orthosis Proximal Cuff

The primary purpose of this research study is to determine if forces within carbon fiber custom dynamic orthoses (CDOs) can be reliability assessed using Loadp…

University of IowaNCT06127264

Actual pay is set by the research site.

Sleep Promoting Intervention to Improve Diabetes Outcomes and Executive Function in Adolescents With T1D

The goal of this work is to conduct a randomized trial evaluating the effects of a behavioral intervention to increase sleep duration and quality for adolescen…

Type 1 Diabetes

Vanderbilt University Medical CenterNCT06516614

Actual pay is set by the research site.

Prospective Clinical Evaluation of Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Patients With Sarcoma

The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in t…

Sarcoma

Wake Forest University Health SciencesNCT06958107

Actual pay is set by the research site.

Phase 1

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult participant (≥1…

Advanced Or Metastatic Merkel Cell Carcinoma

TuHURA Biosciences, Inc.NCT06940440

~$150 – $4,200

Actual pay is set by the research site.

Neurological DisorderALS (Amyotrophic Lateral Sclerosis)Motor Neuron Disease+2 more

INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study